Board of Directors
- David Auth, Ph.D.
Dr. Auth received his Ph.D. in Physics from Georgetown University in 1969, and joined the faculty of Electrical Engineering at the University of Washington that year. He taught electrical engineering and the newly-created field of bioengineering there for 13 years, and ran a lab that integrated both fields. Dr. Auth and his graduate students pioneered several new medical device platform technologies including contact laser surgery, ophthalmic holography, and transendoscopic limited injury hemostasis resulting in the fast pulse thermal cautery probe which was licensed by the University of Washington to Olympus Corp. (Olympus HPU®) With his students he performed the seminal investigation of impedance limited, controlled injury, multipolar cauterization leading to two highly successful inventions: American Cystoscope BICAP® and the Novacept/CYTYC/Hologic global endometrial ablation device Novasure® (2009 revenue of approx. $300 million).
He left academia in 1982 to become Director of New Product Ventures for Squibb Medical Systems Group, then he started the Biophysics International division of E.R. Squibb and Sons, Inc. He continued with Squibb until 1989, when he founded Heart Technology, Inc. to develop and commercialize his rotational atherectomy (Rotablator®) device. The Rotablator® is a catheter-based device that uses high speed rotational ablation to remove atherosclerotic plaque from coronary arteries. Dr. Auth ran Heart Technology as its CEO for six years, growing it to 500 employees and $80 million in revenue, before it was sold to Boston Scientific for $600 million in 1995.
In addition to Arstasis, Dr. Auth is Chairman and CEO of Coaptus Medical Corporation and serves on the boards of directors of eight medical device companies. He has previously served on the boards of Integra LifeSciences, Novacept and Radiotherapeutics. . He has maintained his ties with academia serving since 1985 as an Affiliate Professor of Bioengineering at the University of Washington. He is a registered professional electrical engineer in the State of Washington and a member of the National Academy of Engineering.
- Scott Hassan
Scott has been a driving force behind some of the most influential Internet companies and projects. He was the founder of eGroups (now Yahoo! Groups) and was the key software architect and developer of Google, Alexa Internet and the Stanford Digital Library. Scott invests in start-ups that aim to make fundamental quality of life improvements for citizens around the world.
Scott Hassan is the President and CEO of Suitable Technologies. He created it with the goal of redefining presence, by giving people the power to choose when and where to be present, regardless of geographic location. Prior to Suitable, Scott founded Willow Garage, combining his belief in open source technology and his passion for bringing robotics into everyday life.
- D. Bruce Modesitt
Mr. Modesitt is a recognized leader in the Arteriotomy and hemostasis field, having been the primary inventor and designer of the Perclose percutaneous remote suturing device, the Closer. The Closer generated over $100 million in revenue during the first year of sales. In August 2004, Mr. Modesitt incorporated Arstasis to develop the self-sealing arteriotomy access device he invented. From August 2004 through November 2011, Mr. Modesitt recruited key employees, consultants, suppliers, directors, and investors for Arstasis, and managed the company to commercialization as its President and CEO. From November 2011 to present Mr. Modesitt has served as CTO of Arstasis.
From 2000 through 2005, Mr. Modesitt worked at Fogarty Research & Development and as an independent consultant to medical device manufacturers, developing medical devices for vein harvesting, vein stripping, side branch management, remote endarterectomy, abdominal aortic aneurysm repair, thoracic aortic aneurysm repair and percutaneous heart valve repair. Earlier, Mr. Modesitt worked as an engineer at Progressive Angioplasty Systems (PAS). At PAS, Mr. Modesitt was the primary inventor and designer of the Paragon™ coronary stent, before PAS was sold to US Surgical in August of 1997 for $150 million. Mr. Modesitt holds over thirty US patents in the medical device field.
Mr. Modesitt was awarded a B.S.M.E. degree from Arizona State University in 1982.
- Lewis Pell
Mr. Pell is one of the most prolific and successful medical technology investors. Since 1975, Mr. Pell has been the lead investor or co-founder of 24 medical device manufacturers, eight of which have been sold for a collective net gain of $1.6 billion. The syndicate of investors he leads into his financings includes dozens of the world’s leading cardiologists, and many former executives of the world’s largest healthcare companies.
Mr. Pell’s medical technology company-founding began in 1975, the year he co-founded Machida America, with Katsumi Oneda, to sell flexible endoscopes. In 1979 he created Pentax Precision Instruments, which he sold eleven years later to Asahi Optical. In 1983 he co-founded American Endoscopy, which made endoscope accessories and was acquired by C.R. Bard in 1986. In 1984 he co-founded Versaflex which made angioplasty balloons and was acquired by Medtronic in 1988. In 1989 he co-founded Heart Technology (with fellow Arstasis board member David Auth) to create and launch the Rotablator, which went public in 1992 and was acquired by Boston Scientific in 1995. In 1991 Mr. Pell co-founded InStent, Inc. to develop self-expanding coronary stents. InStent went public in 1995 and was acquired by Medtronic in 1996. In 1992 he co-founded Vision Sciences to develop disposable endoscope sheaths with tool channels. In 1994 Mr. Pell co-founded Biosense to develop three-dimensional cardiac mapping software for electrophysiologists. Biosense was acquired by Johnson & Johnson in 1997. Also in 1994, Mr. Pell co-founded Influence, Inc., to sell incontinence products, which was acquired by American Medical Systems in 1999. In 1998 he co-founded Disc-O-Tech, to develop a portfolio of orthopedic devices that was sold to Kyphon in 2007 for $240 million.
In 2006, Mr. Pell became the lead investor and chairman of Arstasis. Mr. Pell continues to serve as chairman of the boards of 13 companies, including Arstasis.